Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15810MR)

This product GTTS-WQ15810MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15810MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5445MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ1031MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ9422MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ12840MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ5886MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ12611MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ13863MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ396MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 2xCon4C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW